Abstract: The present application relates to methods of treating, managing and/or preventing cancer, comprising administering (a) a protein that comprises (i) an antigen-binding site that binds an antigen on a natural killer (NK) cell, and (ii) an antigen-binding site that binds an antigen on a cell of said cancer; and (b) iberdomide (CC-220), avadomide (CC-122), lenalidomide, pomalidomide, or CC-92480. The present application also relates to methods of treating, managing and/or preventing cancer, comprising administering (a) a protein that comprises (i) an antigen-binding site that binds NKG2D, and (ii) an antigen-binding site that binds an antigen on a cell of said cancer, and (ii) an antigen-binding site that binds an antigen on a cell of said cancer; and (b) iberdomide (CC-220), avadomide (CC-122), lenalidomide, pomalidomide, or CC-92480.

Abstract: The disclosure relates to agents for use in the treatment or prevention of a cytokine-related adverse event or disease, such as cytokine release syndrome (CRS).

Abstract: The present invention relates to diagnostic methods that are relevant to various cancers and which comprise improvements on a BH3 profiling diagnostic method.

Abstract: Sulfamoyl-containing compounds are disclosed, having utility as inhibitors of disease-related targets, such as Heat Shock Protein 90 (HSP90), and which are useful for treating disorders, e.g., proliferative disorders, including HSP90-mediated disorders. Methods for preparing and using the disclosed compounds are also described.

Abstract: Methods of the invention comprise assays for markers indicative of cancer, precancer, and other diseases or disorders. Assays of the invention are preformed on heterogeneous samples obtained from patients by non-invasive or minimally-invasive methods.

Abstract: Methods for detecting nucleotide deletions in biological samples are described. Methods of the invention are particulary useful for detecting deletions in regions of polynucleotide repeats. In particular, methods of the invention are useful to detect deletions at the BAT26 locus.

Abstract: Methods of the invention comprise assays for markers indicative of cancer, precancer, and other diseases or disorders. Assays of the invention are preformed on heterogeneous samples obtained from patients by non-invasive or minimally-invasive methods. Such assays may be employed alone or in combination with other disease screening techniques.

Abstract: Methods of the invention comprise assays for markers indicative of cancer, precancer, and other diseases or disorders. Assays of the invention are preformed on heterogeneous samples obtained from patients by non-invasive or minimally-invasive methods. Such assays may be employed alone or in combination with other disease screening techniques.

Abstract: Methods for detecting nucleotide deletions in biological samples are described. Methods of the invention are particulary useful for detecting deletions in regions of polynucleotide repeats. In particular, methods of the invention are useful to detect deletions at the BAT26 locus.

Abstract: Methods of the invention comprise assays for markers indicative of cancer, precancer, and other diseases or disorders. Assays of the invention are preformed on heterogeneous samples obtained from patients by non-invasive or minimally-invasive methods. Such assays may be employed alone or in combination with other disease screening techniques.

Abstract: Methods for detecting a nucleotide insertion or deletion in biological samples are described. Methods of the invention are particulary useful for detecting a nucleotide insertion or deletion in regions of polynucleotide repeats. In particular, methods of the invention are useful to detect a nucleotide insertion of deletion at the BAT26 locus.